CD36 and neoplasm: However, when we focused on the subgroup of patients with a DFS of less than 12 months, we found that DFS for patients with CD36-positive tumours was two months shorter than for those with CD36-negative tumours (6.51 vs. 8.74 months; p = 0.049), indicating that CD36 positivity was linked to more aggressive tumours.